Investigating how sympathetic blockade affects glucose production in obese hypertensive individuals
Official title: Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity, Crossover Design Study.
Run by Vanderbilt University Medical Center · NCT05312892 · Data updated 2026-11-12
This study is testing if a new treatment can help people who are obese and have high blood pressure improve their blood sugar levels.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 12 (estimated) |
| Sponsor | Vanderbilt University Medical Center Academic / other |
| Locations | 1 site (Nashville, Tennessee) |
| Status | Recruiting |
| Started | May 20, 2022 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2030 |
| Registry record updated | February 27, 2026 |
| Trial ID | NCT05312892 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are males and females aged 18 to 65 with obesity (BMI ≥ 30 kg/m2) and hypertension.
✕Probably not a fit
Patients with type I diabetes, significant cardiovascular disease, or those who are pregnant or breastfeeding may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial examines the effects of sympathetic blockade on endogenous glucose production in obese hypertensive subjects through a randomized, crossover design. Participants will receive either a placebo, amlodipine, or moxonidine over a two-week period, with the treatment order determined by randomization. The study aims to assess whether these interventions can improve glucose metabolism in this population. Data analysis will be conducted by an investigator who is blinded to the treatment assignments to ensure objectivity.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for obesity and hypertension, potentially enhancing glucose metabolism in affected patients.
How similar studies have gone: Other studies have explored sympathetic blockade in relation to obesity and hypertension, but this specific crossover design may offer novel insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Males and females of all races between 18 and 65 years of age * Hypertension defined by two or more properly measured seated blood pressure readings \>130/85 mmHg or currently on antihypertensive medication. * Obesity will be defined as having a body mass index (BMI) ≥ 30 kg/m2. * Able and willing to provide informed consent. Exclusion Criteria: * Pregnancy or breast feeding * Current smokers or history of heavy smoking (\>2 packs/day) * History of alcohol or drug abuse * Previous allergic reaction to study medications * Type I diabetes. * Cardiovascular disease other than hypertension such as myocardial infarction within 6 months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy * History of serious cerebrovascular disease such as cerebral hemorrhage, stroke, or transient ischemic attack * History or presence of immunological or hematological disorders * Impaired renal function * Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive days in 1 month) * Treatment with any investigational drug in the 1 month preceding the study * Inability to give, or withdraw, informed consent * Other factors which in the investigator's opinion would prevent the subject from completing the protocol (i.e., clinically significant abnormalities on clinical, mental examination or laboratory testing or inability to comply with protocol, inability to find IV access)
Where it's running
-
Vanderbilt University Medical Center
Nashville, Tennessee, United States Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Clazakizumab for adults with high hsCRP at risk for a heart event
This study tests whether clazakizumab can lower inflammation and reduce cardiovascular risk in adults with high hsCRP and existing risk factors.
-
Structured management of adult cardiovascular risk factors in outpatient care
This project will try a structured clinic approach to managing blood pressure, cholesterol, diabetes, and weight in adults with cardiovascular risk factors to see if it improves risk control and outcomes.
-
Digital tool for doctors to prescribe exercise for people with cardiovascular risk factors
This project will test whether a new digital tool helps doctors create personalized exercise plans for adults with cardiovascular risk factors.
-
Postpartum program to prevent cardiometabolic problems after preeclampsia
This study will test a 9-month app-based support program to lower blood pressure and help with weight loss in first-time mothers who recently had preeclampsia.
-
Sisters of Heart: community health worker support to improve heart health in migrant farmworker women
This trial tests whether peer support and help accessing community resources from community health workers can reduce stress and improve heart health measures in Spanish- or English-speaking migrant farmworker women aged 18–45.
-
Oral SPM-enriched marine oil to reduce inflammation-driven vascular ageing in obese people with high blood pressure
This trial tests whether taking an oral SPM-enriched marine oil supplement (LIPINOVA) can reduce blood-vessel inflammation and signs of vascular ageing in adults with obesity and controlled hypertension.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.